Jakob Loven ^Investor

Jakob Loven is a seasoned Managing Partner at Nextech Invest Ltd., with a strong background in biotechnology and life sciences. He serves on multiple boards, including A2 Biotherapeutics, Arrakis Therapeutics, and Boundless Bio, showcasing his expertise in the industry. Jakob's research on MYCN-driven miRNAs in neuroblastoma patients has been published in reputable journals, highlighting his contributions to the field. With a Ph.D. in Medical Sciences and experience at Third Rock Ventures, Jakob is a respected figure in the biotech community. His interests in data science and super-enhancers demonstrate his commitment to innovation and cutting-edge research. Connect with Jakob on LinkedIn for insights into the biotech industry.